Dementia, Alzheimer Type: Clinical Trials

26 trials for Dementia, Alzheimer Type, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 4 unknown, 2 active not recruiting, 2 recruiting. 11 Not applicable, 4 Phase 2, 4 Phase 3, 2 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable11Completed 6, Active not recruiting 2, Unknown 2, Recruiting 1
Phase 24Completed 2, Terminated 1, Unknown 1
Phase 34Completed 4
Phase 42Completed 2

Follow Dementia, Alzheimer Type: new trials by email Literature Review of Dementia, Alzheimer Type trials Research Report on Dementia, Alzheimer Type

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
Dementia, Alzheimer Type, Mild Cognitive Impairment
RecruitingUniversity Hospital, Essen152022-08-152025-09-04
Association of Cognition With Functional Mobility in People With Alzheimer's Disease
Alzheimer Dementia, Alzheimer's Disease
UnknownIstanbul University - Cerrahpasa642021-11-012021-11-09
Deep Brain Stimulation for Alzheimer's Disease
Deep brain stimulation, Best medical treatment for Alzheimer's disease - Alzheimer Disease, Dementia, Alzheimer Type
Not applicableUnknownBuddhist Tzu Chi General Hospital302020-04-062020-07-17
Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)
ABC Clinical Program, BCN - Dementia, Alzheimer Type
Not applicableCompletedIndiana University532019-11-252024-09-19
Intervention of Intestinal Microorganism in Mild Cognitive Impairment
Probiotic supplemented intervention, Placebo - Gut Microbiota, Mild Cognitive Impairment
Not applicableCompletedXuanwuH 2902019-08-312022-07-13
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
Physical activity, Successful Aging - Dementia, Alzheimer Type
Not applicableRecruitingPennington Biomedical Research Center1252019-08-092024-11-25
Targeting Brain Physiology to Treat Neuropsychiatric Symptoms of Dementia Using TMS-EEG and tDCS
Transcranial Direct Current Stimulation (tDCS) - Alzheimer Disease, Dementia, Mixed
Not applicableActive not recruitingCentre for Addiction and Mental Health902019-04-242026-04-13
Movement Intervention for Memory Enhancement
Social Dancing, Treadmill Walking - Alzheimer Disease, Dementia
Not applicableCompletedAlbert Einstein College of Medicine252019-03-282021-08-16
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
Renew NCP-5 - Alzheimer Disease, Cognitive Dysfunction
Phase 3CompletedRenew Research, LLC1902018-11-122022-05-11
Studies of Brain and Body Interaction
Autistic Disorders Spectrum, Adhd
CompletedRutgers University302018-08-012026-04-29
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
GammaSense Stimulation System (non-invasive, non-significant risk) - Alzheimer Disease, Early Onset, Alzheimer Disease
Not applicableUnknownCognito Therapeutics, Inc.202018-05-312021-08-24
Multi-Center Study of Sensory Stimulation to Improve Brain Function
GammaSense Stimulation System (Active Settings), GammaSense Stimulation System (Sham Settings) - Alzheimer Disease, Cognitive Impairment
Not applicableActive not recruitingCognito Therapeutics, Inc.602018-04-242021-08-24
Partners at Meals - Respite Care and Home (PAM)
Partners at Meals, Enhanced Usual Condition - Dementia, Alzheimer Type, Weight Loss
Not applicableCompletedMedical University of South Carolina1062017-08-152025-04-10
Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)
Vielight Neuro Gamma - Dementia, Alzheimer Type
Not applicableCompletedUniversity of California, San Francisco202017-05-152020-10-06
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Xanamem™, Placebo (for Xanamem™) - Dementia, Alzheimer Type
Phase 2CompletedActinogen Medical1852017-03-232025-02-03
Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)
MoCA - Cognitive Impairment, Cognitive Decline
CompletedAndreas Monsch3342016-12-012018-05-31
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
Alzheimer Disease, Early Onset, Alzheimer Disease
CompletedUniversity of California, Los Angeles1802016-04-042025-04-30
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
E2609, Placebo - Alzheimer Disease, Dementia, Alzheimer Type
Phase 2TerminatedEisai Inc.702014-11-262021-03-05
Home Evaluation of Exit Barriers in Wandering
Door cover/Floor cover - Dementia, Alzheimer Type, Problem Behavior
Not applicableCompletedUS Department of Veterans Affairs192009-10-012014-11-21
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
Memantine, Donepezil - Dementia, Alzheimer Type
Phase 4CompletedHospital Miguel Servet642007-07-012008-12-29

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Alzheimer Disease (26)  ·  Dementia (10)  ·  Cognitive Dysfunction (9)  ·  Lymphoma, Follicular (3)  ·  Mental Disorders (2)  ·  Psychomotor Agitation (2)  ·  Aberrant Motor Behavior in Dementia (1)  ·  Amyloid Neuropathies, Familial (1)  ·  Aphasia, Primary Progressive (1)  ·  Apraxia, Ideomotor (1)  ·  Apraxias (1)  ·  Asperger Syndrome (1)  ·  Attention Deficit Disorder with Hyperactivity (1)  ·  Child Development Disorders, Pervasive (1)  ·  Cognition Disorders (1)

Broader conditions

Brain Diseases (26)  ·  Central Nervous System Diseases (26)  ·  Nervous System Diseases (26)  ·  Neurocognitive Disorders (26)  ·  Neurodegenerative Diseases (26)  ·  Tauopathies (26)  ·  Mental Disorders (24)  ·  Dementia (16)  ·  Cognition Disorders (8)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (6)  ·  Behavior (5)  ·  Neurologic Manifestations (5)  ·  Neurobehavioral Manifestations (4)  ·  Behavioral Symptoms (3)

Interventions

Memantine (2)  ·  Amyloid beta-Protein Precursor (1)  ·  Aripiprazole (1)  ·  Deep Brain Stimulation (1)  ·  Donepezil (1)  ·  Exercise (1)  ·  Olanzapine (1)  ·  Quetiapine Fumarate (1)  ·  Risperidone (1)  ·  Rivastigmine (1)  ·  Transcranial Direct Current Stimulation (1)  ·  UE2343 (1)  ·  Valproic Acid (1)

Sponsors

Cognito Therapeutics, Inc. (2)  ·  Actinogen Medical (1)  ·  Albert Einstein College of Medicine (1)  ·  Andreas Monsch (1)  ·  Buddhist Tzu Chi General Hospital (1)  ·  Centre for Addiction and Mental Health (1)  ·  Eisai Inc. (1)  ·  Emory University (1)  ·  Hospital Miguel Servet (1)  ·  Indiana University (1)  ·  Istanbul University - Cerrahpasa (1)  ·  Medical University of South Carolina (1)  ·  National Taiwan University Hospital (1)  ·  Novartis Pharmaceuticals (1)  ·  Otsuka Pharmaceutical Development & Commercialization, Inc. (1)

Countries

United States (16)  ·  Taiwan (3)  ·  Germany (2)  ·  Australia (1)  ·  Canada (1)  ·  Chile (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  Guatemala (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)  ·  Mexico (1)

Top investigators

Alan Boyd, MD, FFPM (1)  ·  Alessandra Thomann, MSc (1)  ·  Andreas Monsch, PhD (1)  ·  Bill Ketelbey, MD (1)  ·  Billy Tally (1)  ·  Claude M Wischik, MBChB (1)  ·  Dorothy H Moore, PhD MA BSW (1)  ·  Evan R Hempel (1)  ·  Helena Blumen, PhD (1)  ·  Joe Verghese, MBBS (1)  ·  Larry E. Tune, MD, MAS (1)  ·  Laura N Gitlin, Ph.D (1)  ·  Linda L Chao, PhD (1)  ·  Malaz Boustani, MD, MPH (1)

Results publications

PMID 19874395, PMID 20810376, PMID 20921879, PMID 21312297, PMID 25550228, PMID 27681702, PMID 33431027, PMID 34630050, PMID 38515445, PMID 38848180, PMID 40082316

NIH funding

1RF1AG050967-01A1 (1), 2014 (1), R01AG062200 (1), R21AG057586 (1), R21AG062966 (1)